Introduction: just recently, it has been established that the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism is linked
Introduction
Gliomas are the most common primary intraparenchymal tumors of the central nervous system (CNS) with a very poor prognosis. They represent approximately 26% of all primary brain and other CNS tumors and 81% of the malignant tumors. Glioblastoma accounts for the majority of gliomas (56.6%). Relative survival estimates for glioblastoma are quite low with only 5.6% of patients who survived five years post diagnosis [1] . Historically gliomas have been classified according to the World Health Organization (WHO) criteria that are determined by histopathological examinations such as nuclear atypia, cellular pleomorphism, mitotic activity, vascular thrombosis, microvascular proliferation and necrosis [2] . Recently, in May 2016, a WHO reclassification of CNS tumors was established where the main change was the use of molecular parameters for diagnosis. Major restructuring of diffuse gliomas with incorporation of genetically defined entities was proposed [3] . This new classification is appropriate and makes a significant advance, because therapeutic targets are greatly dependent on the molecular mechanisms of gliomas, and tumors diagnosed in the same group have different gene expression profiles identified by large-scale genomic DNA analyses, including gene expression profiling, genome-wide association studies and single-nucleotide polymorphism analysis [4] . Furthermore, several environmental factors such as therapeutic ionising radiation, electrical or electronics jobs, long-term use of wireless phones, etc.
have been correlated with an increased risk of developing gliomas.
Genetic factors, using three signaling pathways: p53, retinoblastoma (RB), and receptor tyrosine kinase (RTK) play crucial roles in glioma development, particularly mutations in isocitrate dehydrogenase 1 and 2, 1p and 19q co-deletion [5] [6] [7] . The identification of genetic, epigenetic and transcriptional abnormalities in the various types of gliomas helps understanding the pathogenesis, predicts prognosis and response to therapy and may serve as diagnostic markers.
Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that converts the inactive decapeptide angiotensin I to the vasoactive angiotensin II while inactivating an angiogenic agent, namely the vasodilator peptide bradykinin.
ACE is a member of the renin-angiotensin system (RAS) expressed in many tissues. Several findings have shown that the ACE inhibitors may possibly reduce the incidence of cancer and may protect against it [8, 9] . Their effect on tumor cells can be attributed to their reducing cell proliferation and migration, inflammation and angiogenesis [8, 9] .
Other research works reported an inhibition of the cellular matrix metalloprotease activity and a reduced expression of vascular endothelial growth factor (VEGF) by ACE inhibitors [9, 10] Statistics: descriptive statistics were performed in terms of means and percentages. The bivariate analysis used contingency tables and chi-square test to compare the genotype distribution between the two groups and crude odds ratio were calculated within a 95% confidence interval while p-value was calculated by Fisher's exact test. P values were considered statistically significant if they were below 0.05.
Statistical analysis was performed using PRISM software, version 5.5.
Ethical considerations: the study was approved by an official review board and a declared consent was signed by patients themselves, their parents or legal tutors before blood sampling.
Results
Characteristics of the considered population are shown in Table 1 . of cancer have been proposed [20] and they are connected to many biochemical pathways including the RAS whose role in CNS tumors has led to an increasing interest among researchers. Classically, the RAS has been studied as a fundamental component of cardiovascular homeostasis, playing a critical role in cardiovascular system, balance of water and electrolytes and cell growth [8, 21, 22] . However, RAS also is expressed in several tissues and organs (liver, kidneys, pancreas, reproductive organs, and brain). Some of these local effects are related to carcinogenesis and gliomagenesis [8] . In another recent study in Indian population: ACE DD genotypes were highly presented in glioma cases compared to controls with 26.8% and 10.6%, respectively (p<0.0001) and conferred 5-fold risk for predisposition in glioma cases. Per copy D allele frequency was found higher in glioma cases than in controls (54% and 25%, respectively, p<0.0001) [14] . No similar studies were found in North Africa. For instance, a Moroccan study summarized 3 research works with 65, 62
and 34 patients, on the frequency of altered genes in patients with glioblastoma, where only alteration of IDH1/2, p53 and EGFR expression were analysed [27] . The frequency of these gene mutation 
Conclusion
The obtained data suggest that the ACE I/D polymorphism could be a risk factor for glioma. However, this has to be confirmed with additional studies considering large samples of different ethnical groups.
What is known about this topic  Renin-angiotensin system blockade may be used in a future as treatment or preventing glioma.
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